119 related articles for article (PubMed ID: 7104163)
1. Pharmacokinetics of azapropazone in the elderly.
Ritch AE; Perera WN; Jones CJ
Br J Clin Pharmacol; 1982 Jul; 14(1):116-9. PubMed ID: 7104163
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of azapropazone following single oral and intravenous doses.
Breuing KH; Gilfrich HJ; Meinertz T; Jähnchen E
Arzneimittelforschung; 1979; 29(6):971-2. PubMed ID: 582795
[TBL] [Abstract][Full Text] [Related]
3. [Human pharmacokinetics of different i.v. doses of azapropazone (HPLC-determination) (author's transl)].
Gikalov I; Kaufmann R; Schuster O
Arzneimittelforschung; 1982; 32(4):423-6. PubMed ID: 7201814
[TBL] [Abstract][Full Text] [Related]
4. Disposition of azapropazone in chronic renal and hepatic failure.
Breuing KH; Gilfrich HJ; Meinertz T; Wiegand UW; Jähnchen E
Eur J Clin Pharmacol; 1981; 20(2):147-55. PubMed ID: 7262176
[No Abstract] [Full Text] [Related]
5. The pharmacology and pharmacokinetics of azapropazone - a review.
Jones CJ
Curr Med Res Opin; 1976; 4(1):3-16. PubMed ID: 770078
[TBL] [Abstract][Full Text] [Related]
6. Concentration of azapropazone in synovial tissues and fluid.
Spahn H; Thabe K; Mutschler E; Tillmann K; Gikalov I
Eur J Clin Pharmacol; 1987; 32(3):303-7. PubMed ID: 3595703
[TBL] [Abstract][Full Text] [Related]
7. [Kinetics of digitoxin during antirheumatic therapy with azapropazone (author's transl)].
Faust-Tinnefeldt G; Gilfrich HJ
Arzneimittelforschung; 1977; 27(10):2009-11. PubMed ID: 579114
[TBL] [Abstract][Full Text] [Related]
8. The uricosuric action of azapropazone: dose-response and comparison with probenecid.
Higgens CS; Scott JT
Br J Clin Pharmacol; 1984 Sep; 18(3):439-43. PubMed ID: 6487482
[TBL] [Abstract][Full Text] [Related]
9. Plasma protein binding of azapropazone in patients with kidney and liver disease.
Jähnchen E; Blanck KJ; Breuing KH; Gilfrich HJ; Meinertz T; Trenk D
Br J Clin Pharmacol; 1981 Apr; 11(4):361-7. PubMed ID: 7259929
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic investigation of the interaction of azapropazone with phenytoin.
Geaney DP; Carver JG; Davies CL; Aronson JK
Br J Clin Pharmacol; 1983 Jun; 15(6):727-34. PubMed ID: 6871071
[TBL] [Abstract][Full Text] [Related]
11. Distribution of azapropazone and its principal 8-hydroxy-metabolite in plasma, urine and gastrointestinal mucosa determined by HPLC.
Rainsford KD
J Pharm Pharmacol; 1985 May; 37(5):341-5. PubMed ID: 2862244
[TBL] [Abstract][Full Text] [Related]
12. A study of the potential interactions between azapropazone and frusemide in man.
Williamson PJ; Ene MD; Roberts CJ
Br J Clin Pharmacol; 1984 Oct; 18(4):619-23. PubMed ID: 6487503
[TBL] [Abstract][Full Text] [Related]
13. Interaction between azapropazone and warfarin.
McElnay JC; D'Arcy PF
Br Med J; 1977 Sep; 2(6089):773-4. PubMed ID: 912313
[No Abstract] [Full Text] [Related]
14. [Azapropazone plasma levels under simultaneous treatment with an antacid or laxative].
Faust-Tinnefeldt G; Geissler HE; Mutschler E
Arzneimittelforschung; 1977; 27(12):2411-4. PubMed ID: 580058
[TBL] [Abstract][Full Text] [Related]
15. Azapropazone and renal function.
Templeton JS
Rheumatol Rehabil; 1978 Nov; 17(4):219-21. PubMed ID: 734316
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of azapropazone on neutrophil migration in anaesthetized swine using a multichamber blister suction technique.
Mousa SA; Brown R; Chan Y; Hsieh J; Smith RD
Br J Pharmacol; 1990 Feb; 99(2):233-6. PubMed ID: 2158370
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic evaluation of the effect of azapropazone on the gastric mucosa.
Hradsky M; Bruce L
Scand J Rheumatol; 1978; 7(1):31-2. PubMed ID: 675173
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition of xanthine oxidase by azapropazone and 8-hydroxy-azapropazone.
Jahn U; Thiele K
Arzneimittelforschung; 1988 Apr; 38(4):507-8. PubMed ID: 3401265
[TBL] [Abstract][Full Text] [Related]
19. The determination of azapropazone in blood plasma.
Leach H
Curr Med Res Opin; 1976; 4(1):35-43. PubMed ID: 1261300
[TBL] [Abstract][Full Text] [Related]
20. Reversible non-oliguric impairment of renal function during azapropazone treatment.
Sipilä R; Skrifvars B; Törnroth T
Scand J Rheumatol; 1986; 15(1):23-6. PubMed ID: 3961430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
